CG Oncology, Inc. CGON
70.35 USD -2.26 (-3.11%)
Nov 12, 2026, 2:31 PM EST
67.43 Day range 72.96
37.01 52-week range 80.97
- YTD
- +69.44%
- 1 year
- +78.51%
Benzinga news
benzinga.com Guggenheim Maintains Buy on CG Oncology, Lowers Price Target to $89 Guggenheim analyst Michael Schmitz maintains CG Oncology (NASDAQ:CGON) with a Buy and lowers the price target from $90 to $89.
benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session Gainers Obsidian Therapeutics (NASDAQ:OBX) stock increased by 27.7% to $12.26 during Friday's regular session. The company's market cap stands at $593.0 million. TransMedics Group (NASDAQ:TMDX)…- benzinga.com CG Oncology Q3 EPS $(0.64) Beats $(0.82) Estimate, Sales $1.604M Beat $643.584K Estimate CG Oncology (NASDAQ:CGON) reported quarterly losses of $(0.64) per share which beat the analyst consensus estimate of $(0.82) by 21.95 percent. This is a 12.28 percent decrease over losses of $(0.57)…
benzinga.com 10 Health Care Stocks Whale Activity In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
benzinga.com RBC Capital Maintains Outperform on CG Oncology, Lowers Price Target to $79 RBC Capital analyst Leonid Timashev maintains CG Oncology (NASDAQ:CGON) with a Outperform and lowers the price target from $81 to $79.
benzinga.com Piper Sandler Maintains Overweight on CG Oncology, Raises Price Target to $85 Piper Sandler analyst Kelsey Goodwin maintains CG Oncology (NASDAQ:CGON) with a Overweight and raises the price target from $82 to $85.
benzinga.com Truist Securities Maintains Buy on CG Oncology, Raises Price Target to $85 Truist Securities analyst Gregory Renza maintains CG Oncology (NASDAQ:CGON) with a Buy and raises the price target from $82 to $85.- benzinga.com CG Oncology Q2 EPS $(0.90) Misses $(0.67) Estimate, Sales $1.157M Beat $360.417K Estimate CG Oncology (NASDAQ:CGON) reported quarterly losses of $(0.90) per share which missed the analyst consensus estimate of $(0.67) by 34.33 percent. This is a 66.67 percent decrease over losses of…
- benzinga.com ANI Pharmaceuticals Plans To Appeal Judge Sheldon K. Rennie's Decision To Deny ANI's Post-Trial Motions For New Trial, Judgement; Co. Seeks To Recover Assets' Value Sold to CG Oncology Under 2010 Deal ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) (ANI or the Company) today announced that Judge Sheldon K. Rennie, on July 16, 2026, denied ANI’s post-trial motions for a new trial and judgment as a matter…
- benzinga.com HC Wainwright & Co. Reiterates Buy on CG Oncology, Maintains $100 Price Target HC Wainwright & Co. analyst Andres Y. Maldonado reiterates CG Oncology (NASDAQ:CGON) with a Buy and maintains $100 price target.
- benzinga.com CG Oncology Reports First Results From CORE‑008 Cohort CX Phase 2 Trial - High CR rates at any time observed in the CIS-containing population with 85.7% and 92.3% in the ITT population and Efficacy Evaluable population, respectively- High-Grade - EFS in the overall…
benzinga.com Truist Securities Reiterates Buy on CG Oncology, Raises Price Target to $82 Truist Securities analyst Gregory Renza reiterates CG Oncology (NASDAQ:CGON) with a Buy and raises the price target from $77 to $82.- benzinga.com JP Morgan Maintains Overweight on CG Oncology, Raises Price Target to $96 JP Morgan analyst Brian Cheng maintains CG Oncology (NASDAQ:CGON) with a Overweight and raises the price target from $91 to $96.
benzinga.com CG Oncology Analysts Boost Their Forecasts Following Q1 Earnings CG Oncology (NASDAQ:CGON) reported mixed results for Q1, with losses of 71 cents per share and sales of $1.083 million. Analysts have adjusted price targets.
benzinga.com RBC Capital Maintains Outperform on CG Oncology, Raises Price Target to $81 RBC Capital analyst Leonid Timashev maintains CG Oncology (NASDAQ:CGON) with a Outperform and raises the price target from $79 to $81.
benzinga.com Truist Securities Reiterates Buy on CG Oncology, Raises Price Target to $77 Truist Securities analyst Gregory Renza reiterates CG Oncology (NASDAQ:CGON) with a Buy and raises the price target from $75 to $77.
benzinga.com Wedbush Maintains Outperform on CG Oncology, Raises Price Target to $80 Wedbush analyst Yun Zhong maintains CG Oncology (NASDAQ:CGON) with a Outperform and raises the price target from $77 to $80.
benzinga.com CG Oncology Q1 EPS $(0.71) Misses $(0.57) Estimate, Sales $1.083M Beat $493.182K Estimate CG Oncology (NASDAQ:CGON) reported quarterly losses of $(0.71) per share which missed the analyst consensus estimate of $(0.57) by 24.56 percent. This is a 57.78 percent decrease over losses of…
benzinga.com RBC Capital Maintains Outperform on CG Oncology, Raises Price Target to $79 RBC Capital analyst Leonid Timashev maintains CG Oncology (NASDAQ:CGON) with a Outperform and raises the price target from $73 to $79.- benzinga.com HC Wainwright & Co. Maintains Buy on CG Oncology, Raises Price Target to $100 HC Wainwright & Co. analyst Andres Y. Maldonado maintains CG Oncology (NASDAQ:CGON) with a Buy and raises the price target from $80 to $100.
benzinga.com What Analysts Are Saying About CG Oncology Stock - benzinga.com HC Wainwright & Co. Maintains Buy on CG Oncology, Raises Price Target to $80 HC Wainwright & Co. analyst Andres Y. Maldonado maintains CG Oncology (NASDAQ:CGON) with a Buy and raises the price target from $75 to $80.
benzinga.com CG Oncology Q4 Earnings Report: What Investors Need to Know - benzinga.com CG Oncology Q4 EPS $(0.51) Beats $(0.59) Estimate, Sales $2.322M Beat $1.641M Estimate CG Oncology (NASDAQ:CGON) reported quarterly losses of $(0.51) per share which beat the analyst consensus estimate of $(0.59) by 13.56 percent. This is a 10.87 percent decrease over losses of $(0.46)…
benzinga.com Expert Outlook: CG Oncology Through The Eyes Of 7 Analysts - benzinga.com Truist Securities Maintains Buy on CG Oncology, Raises Price Target to $75 Truist Securities analyst Gregory Renza maintains CG Oncology (NASDAQ:CGON) with a Buy and raises the price target from $66 to $75.
- benzinga.com What Analysts Are Saying About CG Oncology Stock
- benzinga.com RBC Capital Maintains Outperform on CG Oncology, Raises Price Target to $73 RBC Capital analyst Leonid Timashev maintains CG Oncology (NASDAQ:CGON) with a Outperform and raises the price target from $61 to $73.
- benzinga.com Piper Sandler Maintains Overweight on CG Oncology, Raises Price Target to $70 Piper Sandler analyst Kelsey Goodwin maintains CG Oncology (NASDAQ:CGON) with a Overweight and raises the price target from $55 to $70.
- benzinga.com Truist Securities Maintains Buy on CG Oncology, Raises Price Target to $66 Truist Securities analyst Gregory Renza maintains CG Oncology (NASDAQ:CGON) with a Buy and raises the price target from $62 to $66.
benzinga.com Crude Oil Rises Sharply; US Consumer Sentiment Edges Higher In January 
benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session 
benzinga.com CG Oncology, Rich Sparkle Holdings, Liquidia And Other Big Stocks Moving Higher On Friday - benzinga.com CG Oncology Announces Expedited Timeline For Topline Data Readout Now Expected In H1 2026 For Phase 3 PIVOT-006 Clinical Trial In IR NMIBC - PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy for intermediate-risk NMIBC now expected in 1H 2026, nearly one year ahead of schedule- First randomized registrational trial to…
benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session - benzinga.com Wedbush Initiates Coverage On CG Oncology with Outperform Rating, Announces Price Target of $70 Wedbush analyst Robert Driscoll initiates coverage on CG Oncology (NASDAQ:CGON) with a Outperform rating and announces Price Target of $70.
- benzinga.com CG Oncology To Present Topline Data From BOND-003 Cohort P And First Results From CORE-008 Cohort A As Late-Breaking Abstracts At SUO 26th Annual Meeting Cretostimogene demonstrated HG-EFS at 3- 6- and 9-months of 95.7%, 84.6% and 80.4%, respectively, in HR BCG UR Ta/T1 Disease in BOND-003 Cohort P CORE-008 Cohort A Data in HR BCG-Naïve NMIBC…
- benzinga.com Truist Securities Initiates Coverage On CG Oncology with Buy Rating, Announces Price Target of $62 Truist Securities analyst Gregory Renza initiates coverage on CG Oncology (NASDAQ:CGON) with a Buy rating and announces Price Target of $62.
- benzinga.com RBC Capital Maintains Outperform on CG Oncology, Raises Price Target to $61 RBC Capital analyst Leonid Timashev maintains CG Oncology (NASDAQ:CGON) with a Outperform and raises the price target from $53 to $61.
- benzinga.com CG Oncology Q3 EPS $(0.57) Misses $(0.56) Estimate, Sales $1.666M Beat $65.300K Estimate CG Oncology (NASDAQ:CGON) reported quarterly losses of $(0.57) per share which missed the analyst consensus estimate of $(0.56) by 1.24 percent. This is a 90 percent decrease over losses of $(0.30)…
- benzinga.com Guggenheim Initiates Coverage On CG Oncology with Buy Rating, Announces Price Target of $90 Guggenheim analyst Brad Canino initiates coverage on CG Oncology (NASDAQ:CGON) with a Buy rating and announces Price Target of $90.
- benzinga.com JP Morgan Maintains Overweight on CG Oncology, Raises Price Target to $47 JP Morgan analyst Brian Cheng maintains CG Oncology (NASDAQ: CGON) with a Overweight and raises the price target from $41 to $47.
- benzinga.com Morgan Stanley Maintains Overweight on CG Oncology, Raises Price Target to $79 Morgan Stanley analyst Jeffrey Hung maintains CG Oncology (NASDAQ:CGON) with a Overweight and raises the price target from $56 to $79.
- benzinga.com HC Wainwright & Co. Reiterates Buy on CG Oncology, Maintains $75 Price Target HC Wainwright & Co. analyst Andres Y. Maldonado reiterates CG Oncology (NASDAQ:CGON) with a Buy and maintains $75 price target.
- benzinga.com Jones Trading Initiates Coverage On CG Oncology with Buy Rating, Announces Price Target of $50 Jones Trading analyst Soumit Roy initiates coverage on CG Oncology (NASDAQ:CGON) with a Buy rating and announces Price Target of $50.
- benzinga.com Cantor Fitzgerald Reiterates Overweight on CG Oncology, Maintains $75 Price Target Cantor Fitzgerald analyst Josh Schimmer reiterates CG Oncology (NASDAQ:CGON) with a Overweight and maintains $75 price target.
benzinga.com CG Oncology Stock Signals Bullish Momentum Ahead CG Oncology has entered its Phase 2 of the Adhishthana Cycle, signaling a bullish setup. With momentum already building, here's what to track...- benzinga.com HC Wainwright & Co. Reiterates Buy on CG Oncology, Maintains $75 Price Target HC Wainwright & Co. analyst Andres Y. Maldonado reiterates CG Oncology (NASDAQ:CGON) with a Buy and maintains $75 price target.
- benzinga.com HC Wainwright & Co. Reiterates Buy on CG Oncology, Maintains $75 Price Target HC Wainwright & Co. analyst Andres Y. Maldonado reiterates CG Oncology (NASDAQ:CGON) with a Buy and maintains $75 price target.
- benzinga.com CG Oncology Announced Updated Data On BOND-003 Cohort C Showing 12 Additional Patients With High Risk Non-muscle Invasive Bladder Cancer Were In Complete Response At 24 Months, With Complete Response Rate Of 41.8% Robust 24-month complete response (CR) rate of 41.8% observed for cretostimogene monotherapy in patients with high-risk non-muscle invasive bladder cancer (NMIBC) who are unresponsive to Bacillus…